您的位置: 首页 > 农业专利 > 详情页

Use of serelaxin to reduce GDF-15
专利权人:
Novartis AG
发明人:
Prescott, Margaret Forney,Zhang, Yiming,Dahlke, Marion,Severin, Thomas
申请号:
AU2018202289
公开号:
AU2018202289A1
申请日:
2018.03.29
申请国别(地区):
AU
年份:
2018
代理人:
摘要:
#$%^&*AU2018202289A120180426.pdf#####ll: rbr Interwoven NRPortbl DCC RBR 16706400 l.docx-26/03/2018 ABSTRACT Growth differentiation factor 15 (GDF-15) is a stress-responsive cytokine known to be associated with adverse events in heart failure patients. The use of serelaxin has been shown to affect GDF- 15 levels at baseline and decreases in GDF- 15 levels over time. Measuring GDF-15 levels allows a healthcare provider to accurately predict pulmonary load in patients with pulmonary congestion.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充